Cyclin B1 (CCNB1), cyclin B2 (CCNB2), DNA topoisomerase II Alpha (TOP2A) and transcription factor fork head box protein M1 (FOXM1) have already been identified as new targets for the gene therapy of ARDS [8]. This evidence concerns the gene TOP2A and acute respiratory distress syndrome.